Literature DB >> 7661077

Clinicians and patients with hypertension: unsettled issues about compliance.

P Rudd1.   

Abstract

Ambulatory treatment of hypertension depends largely on long-term oral medications to lower blood pressure and delay or prevent cardiovascular morbidity and mortality. Failure to achieve the therapeutic goal may reflect biologic, pharmacologic, or behavioral factors. Ignoring behavioral factors may result in unnecessary or even dangerous regimen escalation. More than half of patients with insufficient reductions in blood pressure display suboptimal medication compliance as assessed by pill count or bioassay. Once-daily dosing may be an important part of enhancing compliance, patient convenience, and regimen simplification; however, drug concentrations may be subtherapeutic when dosing delays or omissions occur. Electronic monitoring data in hypertension, glaucoma, seizure disorders, and other diseases indicate that 50% to 60% of patients adhere well to prescribed regiments, that 5% to 10% adhere poorly, and that the 30% to 45% adhere to an intermediate but markedly variable degree. A growing body of literature offers empirical support for focused and personalized interventions.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7661077     DOI: 10.1016/0002-8703(95)90368-2

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  18 in total

Review 1.  CPAP therapy: outcomes and patient use.

Authors:  N J Douglas; H M Engleman
Journal:  Thorax       Date:  1998-10       Impact factor: 9.139

2.  A computerized tool for evaluating the effectiveness of preventive interventions.

Authors:  G Daumit; L E Boulware; N R Powe; C S Minkovitz; K D Frick; L A Anderson; G R Janes; R S Lawrence
Journal:  Public Health Rep       Date:  2001       Impact factor: 2.792

3.  Observational study of compliance and continuance rates of raloxifene in the prevention and treatment of osteoporosis.

Authors:  José R Zanchetta; Carina Hakim; Carola Lombas
Journal:  Curr Ther Res Clin Exp       Date:  2004-11

4.  Randomised placebo controlled trial of daytime function after continuous positive airway pressure (CPAP) therapy for the sleep apnoea/hypopnoea syndrome.

Authors:  H M Engleman; S E Martin; R N Kingshott; T W Mackay; I J Deary; N J Douglas
Journal:  Thorax       Date:  1998-05       Impact factor: 9.139

Review 5.  Fixed-dose combinations as initial therapy for hypertension: a review of approved agents and a guide to patient selection.

Authors:  Bernard Waeber; François Feihl; Luis M Ruilope
Journal:  Drugs       Date:  2009       Impact factor: 9.546

6.  Electronic pillboxes (MEMS) to assess the relationship between medication adherence and blood pressure control in primary care.

Authors:  Andreas Zeller; Knut Schroeder; Tim J Peters
Journal:  Scand J Prim Health Care       Date:  2007-12       Impact factor: 2.581

7.  Brief-interval telephone surveys of medication adherence and asthma symptoms in the Childhood Asthma Management Program Continuation Study.

Authors:  Bruce G Bender; Allison Rankin; Zung Vu Tran; Frederick S Wamboldt
Journal:  Ann Allergy Asthma Immunol       Date:  2008-10       Impact factor: 6.347

8.  Long-term compliance with continuous positive airway pressure in patients with obstructive sleep apnea.

Authors:  Norman Wolkove; Marc Baltzan; Hany Kamel; Richard Dabrusin; Mark Palayew
Journal:  Can Respir J       Date:  2008-10       Impact factor: 2.409

9.  Antihypertensive medication adherence in cancer survivors and its affecting factors: results of a Korean population-based study.

Authors:  Dong Wook Shin; Jong Hyock Park; Jae Hyun Park; Eun Cheol Park; So Young Kim; Sung Gyeong Kim; Jin Young Choi
Journal:  Support Care Cancer       Date:  2010-01-15       Impact factor: 3.603

10.  Patient recall of medication details in the outpatient clinic. Audit and assessment of the value of printed instructions requesting patients to bring medications to clinic.

Authors:  W Keeble; S M Cobbe
Journal:  Postgrad Med J       Date:  2002-08       Impact factor: 2.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.